

KKR to Acquire Bushu Pharmaceuticals

12.21.22



Simpson Thacher is representing KKR in connection with its announced acquisition of Bushu Pharmaceuticals Ltd. from BPEA EQT. The transaction is expected to be completed in Q1 2023, subject to regulatory approvals and customary closing conditions.

Bushu Pharma is a leading contract development and manufacturing organization (CDMO) in Japan that manufactures products for worldwide end-markets, with a particular focus on Japan and Asian countries, such as China.

The Simpson Thacher team for the transaction includes Noritaka Kumamoto, Jonathan Stradling, Daisuke Ueta and Yuji Yagi (M&A – Tokyo); Ian Ho (M&A – Hong Kong); and Makiko Harunari and Atsushi Usui (Credit).

Team and Contacts

Noritaka Kumamoto

Partner

nkumamoto@stblaw.com

+81-3-5562-6219

Daisuke Ueta

Associate

daisuke.ueta@stblaw.com

+81-3-5562-6237

Ian Ho

Partner

iho@stblaw.com

+852-2514-7685

Atsushi Usui

Registered Foreign Lawyer

atsushi.usui@stblaw.com

Jonathan Stradling

Partner

jonathan.stradling@stblaw.com

+81-3-5562-6224

Yuji Yagi

Associate

yuji.yagi@stblaw.com

+81-3-5562-6282

Makiko Harunari

Partner

mharunari@stblaw.com

+852-2514-7604

